Dose Optimization of MDMA-Assisted Therapy for PTSD
Launched by BRONX VA MEDICAL CENTER · May 13, 2024
Trial Information
Current as of February 18, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This open label, within-subjects dose optimization study will determine the optimal number of treatment cycles of MDMA-AT (one cycle consists of one Experimental Session followed by three Integrative Sessions) for significant improvement in a sample of U.S. veterans with PTSD. All participants will receive three non-drug preparatory sessions and at least one cycle of MDMA-assisted therapy with a team of two therapists. Each cycle will consist of one approximately 8-hour drug session followed by three 90-minute non-drug integrative sessions. After each cycle, participants will determine, in ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Are a U.S. military veteran at least 18 years old.
- • 2. Are able to provide written, informed consent.
- • 3. Are able to swallow pills.
- • 4. Agree to have study visits recorded, including Experimental Sessions, psychological assessments, and non-drug therapy sessions.
- • 5. Must provide a contact who is willing and able to be reached by the investigators in the event of a participant becoming unwell or unreachable.
- • 6. If able to become pregnant, must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate contraceptive methods.
- • 7. Must have a current PTSD diagnosis at screening and baseline.
- • 8. Must not participate in any other interventional clinical trials for the duration of the study.
- • 9. Must commit to medication dosing, therapy, and all study procedures.
- Exclusion Criteria:
- • 1. Are not able to give adequate informed consent.
- • 2. Have a history of any medical condition, or any significant clinical finding on screening tests, that could make receiving a sympathomimetic drug harmful.
- • 3. Have uncontrolled hypertension.
- • 4. Have evidence or history of significant medical or psychiatric disorders.
- • 5. Have symptomatic liver disease.
- • 6. Have history of hyponatremia or hyperthermia.
- • 7. Weigh less than 48 kilograms (kg).
- • 8. Unable or unwilling to safely taper off prohibited psychiatric medication.
- • 9. Abusing illegal drugs or alcohol.
- • 10. Have received Electroconvulsive Therapy (ECT) or ketamine therapy within 12 weeks of enrollment.
- • 11. Are pregnant or nursing or are able to become pregnant and are not practicing an effective means of contraception.
Trial Officials
Rachel Yehuda, PhD
Principal Investigator
James J. Peters VA Medical Center
Amy Lehrner, PhD
Principal Investigator
James J. Peters VA Medical Center
About Bronx Va Medical Center
The Bronx VA Medical Center is a leading healthcare institution dedicated to providing comprehensive medical services and advancing clinical research for veterans. As a prominent sponsor of clinical trials, the center focuses on innovative therapies and treatments that address the unique health challenges faced by the veteran population. Leveraging a multidisciplinary team of healthcare professionals and researchers, the Bronx VA Medical Center aims to enhance patient care through evidence-based practices and the exploration of cutting-edge medical interventions. Its commitment to improving health outcomes underscores its role as a vital resource in the field of veteran healthcare and medical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0